Withings is back at CES 2026 with another smart scale: the $599.95 Body Scan 2. This time, it’s got an even tighter focus on cardiovascular and metabolic health.
The Body Scan 2 contains eight electrodes on the scale itself, as well as an additional four electrodes within a retractable handle. This is similar to the original Body Scan’s design. Adding the handle makes the Body Scan lineup more accurate than most smart scales because it incorporates upper-body data. Typical smart scales only have foot electrodes, and solely use lower-body data to extrapolate total body composition.
The major difference with the Body Scan 2 is it increases the number of biomarkers tracked. In addition to weight, heart rate, and overall body composition, the scale now adds a 90-second “longevity assessment.” The assessment consists of over 60 biomarkers that are broken down into roughly five categories: heart pumping performance and heart electrical activity, hypertension risk, artery health, cellular health and metabolic efficiency, and glycemic regulation.
“We have been building this vision of adding a lot of powerful biomarkers that can be measured every day when you step on the scale,” says Antoine Joussain, Withings’ director of product management, devices.
Since tracking over 60 metrics can get unwieldy, users will also get a more digestible Health Trajectory score that visualizes their healthspan — or how many years of good health a person can expect.
“We want to keep it simple on a high level, so you have clear indicators that you can follow on a daily, weekly, or monthly basis. The rest of the 60 biomarkers, you can of course review them, but we’ll do all the interpretation for you,” Joussain says.
This isn’t a wholly new concept. Whoop introduced a similar score in 2025 with its Whoop 5.0 tracker using cardiovascular, sleep, and activity metrics to estimate how well a person is aging. Oura also launched metrics for comparing cardiovascular age and chronological age in 2024. Both companies also added on the ability to get blood tests to track metabolic health metrics last year.
But one intriguing thing about Withings’ approach with the Body Scan 2 is it’s tracking metabolic health noninvasively. Instead of blood tests, the scale utilizes something called bioimpedance spectroscopy (BIS) and foot sweat. Yes, foot sweat.
“The goal is to stimulate the sweat glands that are inside your feet with a safe, tiny current. We measure the maximum activity response from these sweat glands. If the activity is high, to simplify a bit, it means your glands are healthy and if not, they’re not healthy,” Joussain explains. He notes that diabetes can cause foot complications, and that Withings has seen correlating evidence from its users who have poorly controlled diabetes.
As for BIS, the scale sends currents at different frequencies to evaluate how well cell membranes are working as another indicator for metabolic health. The benefit of these noninvasive methods, he says, is that they can be taken more frequently and easily than blood tests. That said, these metabolic features aren’t meant to be diagnostic — they’re envisioned more as early warning flags.
The benefit of collecting all this data on a smart scale, Joussain says, is it’s a convenient device many people already have and are accustomed to using regularly. That, he says, makes it the ideal gadget for taking several long-term health measurements at once. But while there’s logic to this approach, there are challenges too. Scales can be emotionally loaded gadgets that some people avoid to prevent body dysmorphia or disordered eating when setting out to improve their overall health.
It’s a problem Withings is aware of. To that end, Joussain points to an Eyes-Closed Mode, in which all measurements are replaced with emoji on the scale but are still recorded in the Withings app. Long-term, he says the hope is to reenvision the scale as a “longevity station” that measures overall health — not just weight.
Another hurdle is regulatory oversight. For the Body Scan 2, two features will require FDA clearance: hypertension risk notifications and the six-lead EKG for atrial fibrillation detection. Compared to other health tech companies, Withings has generally opted for FDA clearance when possible, to mixed results. Its ScanWatch smartwatch, for instance, took nearly two years to make it through the FDA clearance process. To launch its U-Scan urinalysis lab, Withings opted to release device as a wellness gadget instead of seeking clearance. The Move ECG smartwatch was announced in 2019, but has yet to hit the US market.
Here, Joussain is more optimistic. He says Withings is pursuing a “new kind of certification” that will allow the company to get its devices on shelves more quickly without sacrificing scientific research. The scale will also be GDPR and HIPAA compliant, and include ISO 27001 and ISO 27701 privacy and security certifications. If all goes according to plan, the Body Scan 2 should be available sometime in Q2 2026.
